TFA-01 DEVELOPMENT
TFA-01 explores Antcin A’s potential as an anti-inflammatory drug, with canine osteoarthritis as the lead indication. Safety studies, investigational injectable formulation development, CMC, and third-party research are advancing together to build the regulatory evidence base.
LEAD PROGRAM · TFA-01
TFA’s initial commercial focus is companion animal health, with canine OA offering measurable pain and mobility outcomes. Formal studies will evaluate efficacy, repeat-dose safety, dosing, and treatment duration.
TFA-01 DEVELOPMENT TIMELINE
Entries appear in reverse chronological order and identify the date type, development workstream, progress and supporting evidence. Each entry distinguishes completed work, initiated projects and public disclosures.
TFA-01 DEVELOPMENT FRAMEWORK
Each section presents the foundation already in place, work underway and the next verifiable milestone. The five workstreams are connected; progress in one addresses a specific development risk but does not mean the product is approved.
Published studies support GR/GRα-related signaling by Antcin A in defined models. TFA is assessing how those findings apply to its current test articles, batches and canine OA development program.
Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.View progress detailsResearch on strains from multiple sources and their Antcin A content supports controlled cultivation, strain selection, purification, analytical testing and formulation development.
Next milestoneComplete physicochemical validation of the nanoformulation, then advance formal specifications, batch consistency and process scale-up.View progress detailsA 14-day repeat-dose preliminary toxicology study in female rats is complete and a report is available to inform later study design. The Graduate Institute of Animal Vaccine Technology is advancing target-animal safety, toxicology, residue and formulation-related research.
Next milestoneComplete the subsequent regulatory toxicology reports and establish the safe dose range for the purified candidate drug substance and final product under this development program.View progress detailsTFA completed uncontrolled exploratory observations in 15 dogs. The first-stage canine osteoarthritis research agreement has been signed, and preliminary cell-based testing is underway ahead of a standardized study.
Next milestoneComplete the canine OA study under a protocol with prespecified endpoints and a statistical analysis plan, and prepare the study report.View progress detailsTFA is assembling data for a veterinary drug application in Taiwan and planning its U.S. CVM strategy. Partnership and licensing opportunities will be evaluated as the supporting data develop.
Next milestoneObtain regulatory feedback on study design, process specifications and remaining data gaps, then develop a submission plan.View progress details
Preparing interactive model
This model uses a computed conformer from PubChem (NCBI/NLM/NIH), CID 10004121; CAS 163597-24-8, molecular formula C₂₉H₄₂O₄. The source record does not specify the stereochemistry at C25; this view shows one computed conformer. PubChem ↗
01 · Molecule, mechanism & rights
Published studies support GR/GRα-related signaling by Antcin A in defined models. TFA is assessing how those findings apply to its current test articles, batches and canine OA development program.
Published research foundation / program validation underway
Under the publicly filed June 2026 agreement, TFA holds exclusive worldwide rights to develop, commercialize and license the Antcin A platform; ownership of the platform assets remains with the rights holder named in the agreement.
SEC 6-KTFA-01 is centered on Antcin A. Published studies provide mechanistic signals from cell, computational and preclinical models, while global platform rights are exercised under the publicly filed cooperation and licensing structure.
TFA is evaluating how published findings relate to current TFA-01 test articles and batches, while building translational pharmacology data relevant to canine osteoarthritis.
Complete candidate test-article and batch definition and build a program-specific pharmacology package for later safety and clinical work.
Available studies do not establish direct biochemical binding between Antcin A and GR, canine or human clinical efficacy, program-specific pharmacokinetic parameters, or drug approval.
02 · CMC CORE ADVANTAGE
A molecule from a natural source must be consistently sourced, identified, purified and produced to specification. TFA integrates cultivation, screening, analysis, purification, specification development and batch bridging within its CMC program.
TFA is building on its access to Antcin A to establish an integrated quality-control system spanning strain selection, cultivation, content testing, purification and batch traceability.
Sourcing foundation in place / specifications and batch bridging underwayTFA-HPF™ · Hyphal Pairing & Fusion
HPF provides strains for ongoing cultivation and research. It supports TFA’s supply capabilities alongside cultivation processes, quality analysis and downstream processing.
Establish compatible hyphal pairings as the starting point for strain development.
Actual culture-plate photo; numbers and animation illustrate hyphal pairing and fusion.
HPF and the cultivation patents in four jurisdictions are presented separately. The granted patent claims define the scope of protection.
Based on current cultivation capacity in Taiwan and internal assumptions, TFA estimates approximately 2.5 kg of Antcin A content per year within cultivated material. This estimate supports supply planning across multiple batches and development stages; it is not a measure of purified drug-substance output.
WHY KILOGRAM SCALE MATTERS
Repeated preparation, batch comparison, specifications and scale-up are what can turn a rare molecule into a drug-development asset.
Build analytical methods, batch-consistency data and retention-sample management instead of relying on a single sample result.
Plan purification, formulation, stability, toxicology and CMC from a shared material base, reducing waits between stages.
A repeatable, traceable supply chain is an important foundation for later GMP transition, clinical development and licensing.
THREE REFERENCES FOR SUPPLY SCALE
Two public supplier pages list Antcin A in 1 mg research-reagent packs. The retail list prices reflect the date checked, stated purity and pack size; they illustrate the cost of sourcing small research quantities.
The official DailyMed label for FDA-approved YONDELIS® (trabectedin) states that each single-dose vial contains 1 mg. This illustrates the milligram-scale finished-product strength of one high-potency drug.
Official DailyMed label | Updated January 6, 2026NCI reports that supply constraints slowed early paclitaxel development. After a collaborator established sufficient supply, participation in NIH-related trials grew from about 500 people in 1989 to nearly 29,000 in 1998, showing why natural-product development needs scalable supply.
U.S. National Cancer Institute | Taxol - A Success StoryApproximately 2.5 kg per year is TFA’s unaudited internal estimate, as of August 2026, of the Antcin A content equivalent within cultivated material, based on current cultivation capacity in Taiwan and internal assumptions. It is not actual output, GMP-released drug substance, saleable inventory or a supply commitment. External 1 mg list prices illustrate research sourcing costs; the YONDELIS® example illustrates a labeled finished-drug strength; and TFA’s estimate provides a basis for supply planning. These references should not be combined to infer selling prices, finished-dose counts, revenue or valuation.
The Graduate Institute of Animal Vaccine Technology is conducting nanoformulation research aimed at improving the dispersion of lipophilic Antcin A in water, laying the groundwork for development of an injectable formulation.
Aqueous solubility, clarity, particle size, uniformity and stability remain to be validated. A final dosage form or submission-ready formulation specification has not been established.
The public site describes the scale and focus of the research. Strain IDs, individual content measurements, cultivation parameters, selection criteria and purification conditions are available in confidential due diligence materials.
03 · Safety & toxicology
A 14-day repeat-dose preliminary toxicology study in female rats is complete and a report is available to inform later study design. The Graduate Institute of Animal Vaccine Technology is advancing target-animal safety, toxicology, residue and formulation-related research.
Preliminary 14-day repeat-dose study completed | Formal studies advancing
The company completed a 14-day preliminary TF-15 toxicology study in 24 female rats and holds the report, which can inform dose selection and design for later formal studies.
The Graduate Institute of Animal Vaccine Technology is conducting target-animal safety, toxicology, residue and nanoformulation research that must be bridged to current TFA-01 test articles and batches.
Complete the subsequent regulatory toxicology reports and establish the safe dose range for the purified candidate drug substance and final product under this development program.
The preliminary screen was not GLP regulatory toxicology or a long-term safety study. It does not establish canine safety, long-term safety, or the safety of purified Antcin A or a final product.
04 · Canine OA clinical development
TFA completed uncontrolled exploratory observations in 15 dogs. The first-stage canine osteoarthritis research agreement has been signed, and preliminary cell-based testing is underway ahead of a standardized study.
First-stage agreement signed / preliminary cell testing underway
The exploratory observations in 15 dogs provide practical experience that can inform the design of later standardized studies.
The first-stage research agreement for TFA-01 in canine osteoarthritis has been signed. Preliminary cell-based testing and study preparations are underway; subsequent assessments, records and reports will follow the study protocol.
Complete the canine OA study under a protocol with prespecified endpoints and a statistical analysis plan, and prepare the study report.
The 15-dog internal exploration was not a regulatory study and lacks verifiable formal start and end dates, a full protocol, prespecified endpoints, statistical analysis and a signed report. It does not establish efficacy, safety, equivalence or superiority. Launching the later research collaboration is not the same as study completion or a new conclusion.
A veterinary care network in Beijing completed exploratory observations in 15 dogs, documenting changes in mobility before and after treatment. Prior experience with corticosteroid treatment serves only as background context; the observations were not a concurrently controlled study.
Mobility changes recorded before and after treatment
Findings inform the design of subsequent formal studies
No concurrent corticosteroid control group
Phased Research Plan
TFA has engaged a third-party research organization to conduct canine osteoarthritis research. Traceable records, assessments and reports at each stage will inform subsequent decisions.
Evaluate dosing, treatment duration, and changes in pain and mobility under the study protocol, while collecting preliminary safety and tolerability data.
Plan studies comparing TFA-01 with representative existing therapies to evaluate outcomes and appropriate treatment settings.
Evaluate additional indications, including feline chronic gingivostomatitis and dermatitis, and build a separate evidence base for each.
05 · Regulatory strategy & commercialization
TFA is assembling data for a veterinary drug application in Taiwan and planning its U.S. CVM strategy. Partnership and licensing opportunities will be evaluated as the supporting data develop.
Taiwan advancing / U.S. CVM planning
Assembling CMC, safety and canine osteoarthritis data for the Taiwan veterinary-drug pathway.
Planning the data-gap review, advisory support and agency communication strategy.
Evaluating regional licensing, co-development and manufacturing as evidence matures.
TFA has established a cross-market rights and cooperation framework and is organizing development data around Taiwan’s veterinary-drug pathway.
TFA is bringing CMC, safety and canine osteoarthritis data together for regulatory review, while planning advisory support and communications with U.S. CVM.
Obtain regulatory feedback on study design, CMC specifications and remaining data gaps, then develop a submission plan.
Regulatory acceptance of the data, acceptance of the application for review, drug approval, launch timing and commercial outcomes remain uncertain.
PUBLISHED SCIENCE
Cell, absorption-model and preclinical studies do not establish clinical safety or efficacy.
PLATFORM EXPANSION
The current primary development focus for TFA-01.
One potential future veterinary indication for evaluation.
A future research opportunity subject to scientific and clinical review.